XBiotech, Inc. is a biopharmaceutical company. The company is headquartered in Austin, Texas and currently employs 58 full-time employees. The firm is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. The company focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The firm has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The firm has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. The company also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).